National Academies Press: OpenBook
Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×

ACCELERATING THE DEVELOPMENT OF BIOMARKERS FOR DRUG SAFETY

Workshop Summary

Steve Olson, Sally Robinson, and Robert Giffin, Rapporteurs

Forum on Drug Discovery, Development, and Translation

Board on Health Sciences Policy

INSTITUTE OF MEDICINE OF THE NATIONAL ACADEMIES

THE NATIONAL ACADEMIES PRESS

Washington, D.C.
www.nap.edu

Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×

THE NATIONAL ACADEMIES PRESS

500 Fifth Street, N.W. Washington, DC 20001

NOTICE: The project that is the subject of this report was approved by the Governing Board of the National Research Council, whose members are drawn from the councils of the National Academy of Sciences, the National Academy of Engineering, and the Institute of Medicine.

This project was supported by the American Diabetes Association; the American Society for Microbiology; Amgen, Inc.; the Association of American Medical Colleges; AstraZeneca Pharmaceuticals; Blue Cross Blue Shield Association; the Burroughs Wellcome Fund; Department of Health and Human Services (Contract Nos. N01-OD-4-2139 and 223-01-2460); the Doris Duke Charitable Foundation; Eli Lilly & Co.; Entelos Inc.; Genentech; GlaxoSmithKline; the March of Dimes Foundation; Merck & Co., Inc.; Pfizer Inc.; and UnitedHealth Group. Any opinions, findings, conclusions, or recommendations expressed in this publication are those of the author(s) and do not necessarily reflect the view of the organizations or agencies that provided support for this project.

International Standard Book Number-13: 978-0-309-13124-7

International Standard Book Number-10: 0-309-13124-3

Additional copies of this report are available from the

National Academies Press,

500 Fifth Street, N.W., Lockbox 285, Washington, DC 20055; (800) 624-6242 or (202) 334-3313 (in the Washington metropolitan area); Internet http://www.nap.edu.

For more information about the Institute of Medicine, visit the IOM home page at: www.iom.edu.

Copyright 2009 by the National Academy of Sciences. All rights reserved.

Printed in the United States of America

The serpent has been a symbol of long life, healing, and knowledge among almost all cultures and religions since the beginning of recorded history. The serpent adopted as a logotype by the Institute of Medicine is a relief carving from ancient Greece, now held by the Staatliche Museen in Berlin.

Suggested citation: IOM (Institute of Medicine). 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press.

Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×

“Knowing is not enough; we must apply.

Willing is not enough; we must do.”

—Goethe

INSTITUTE OF MEDICINE OF THE NATIONAL ACADEMIES


Advising the Nation. Improving Health.

Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×

THE NATIONAL ACADEMIES

Advisers to the Nation on Science, Engineering, and Medicine


The National Academy of Sciences is a private, nonprofit, self-perpetuating society of distinguished scholars engaged in scientific and engineering research, dedicated to the furtherance of science and technology and to their use for the general welfare. Upon the authority of the charter granted to it by the Congress in 1863, the Academy has a mandate that requires it to advise the federal government on scientific and technical matters. Dr. Ralph J. Cicerone is president of the National Academy of Sciences.


The National Academy of Engineering was established in 1964, under the charter of the National Academy of Sciences, as a parallel organization of outstanding engineers. It is autonomous in its administration and in the selection of its members, sharing with the National Academy of Sciences the responsibility for advising the federal government. The National Academy of Engineering also sponsors engineering programs aimed at meeting national needs, encourages education and research, and recognizes the superior achievements of engineers. Dr. Charles M. Vest is president of the National Academy of Engineering.


The Institute of Medicine was established in 1970 by the National Academy of Sciences to secure the services of eminent members of appropriate professions in the examination of policy matters pertaining to the health of the public. The Institute acts under the responsibility given to the National Academy of Sciences by its congressional charter to be an adviser to the federal government and, upon its own initiative, to identify issues of medical care, research, and education. Dr. Harvey V. Fineberg is president of the Institute of Medicine.


The National Research Council was organized by the National Academy of Sciences in 1916 to associate the broad community of science and technology with the Academy’s purposes of furthering knowledge and advising the federal government. Functioning in accordance with general policies determined by the Academy, the Council has become the principal operating agency of both the National Academy of Sciences and the National Academy of Engineering in providing services to the government, the public, and the scientific and engineering communities. The Council is administered jointly by both Academies and the Institute of Medicine. Dr. Ralph J. Cicerone and Dr. Charles M. Vest are chair and vice chair, respectively, of the National Research Council.


www.national-academies.org

Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×

PLANNING COMMITTEE FOR ASSESSING AND ACCELERATING THE DEVELOPMENT OF BIOMARKERS FOR DRUG SAFETY: A WORKSHOP

Robert Califf (Workshop Chair),

Duke University Medical Center, North Carolina

Garret A. FitzGerald,

University of Pennsylvania School of Medicine

Marlene Haffner,

Amgen, Inc., Washington, DC

Ronald L. Krall,

GlaxoSmithKline, Pennsylvania

William B. Mattes,

Critical Path Institute, Maryland

Aidan Power,

Pfizer Inc., Connecticut

Janet Woodcock,

U.S. Food and Drug Administration, Maryland

Study Staff

Robert B. Giffin, Director

Sally Robinson, Program Officer

Andrea Rebholz, Senior Program Assistant

Genea S. Vincent, Senior Program Assistant

Rona Briere, Consulting Editor

Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×

FORUM ON DRUG DISCOVERY, DEVELOPMENT, AND TRANSLATION1

Gail H. Cassell (Co-Chair),

Eli Lilly and Company, Indiana

Jeffrey M. Drazen (Co-Chair),

New England Journal of Medicine, Massachusetts

Barbara Alving,

National Center for Research Resources, Maryland

Hal Barron,

Genentech, California

Leslie Z. Benet,

University of California, San Francisco

Catherine Bonuccelli,

AstraZeneca Pharmaceuticals, Delaware

Linda Brady,

National Institute of Mental Health, Maryland

Robert M. Califf,

Duke University Medical Center, North Carolina

Scott Campbell,

American Diabetes Association, Virginia

C. Thomas Caskey,

University of Texas-Houston Health Science Center

Peter B. Corr,

Celtic Therapeutics, New York

James H. Doroshow,

National Cancer Institute, Maryland

Paul R. Eisenberg,

Amgen, Inc., California

Garret A. FitzGerald,

University of Pennsylvania School of Medicine

Elaine K. Gallin,

The Doris Duke Charitable Foundation, New York

Steven K. Galson,

Office of the Surgeon General, U.S. Department of Health and Human Services, Maryland

Mikhail Gishizky,

Entelos, Inc., California

Stephen Groft,

National Institutes of Health, Maryland

Edward W. Holmes,

National University of Singapore

Peter K. Honig,

Merck & Co., Inc., Pennsylvania

A. Jacqueline Hunter,

GlaxoSmithKline, United Kingdom

Michael Katz,

March of Dimes Foundation, New York

Jack D. Keene,

Duke University Medical Center, North Carolina

Ronald L. Krall,

GlaxoSmithKline, Pennsylvania

Musa Mayer,

AdvancedBC.org, New York

Mark B. McClellan,

Brookings Institution, Washington, DC

Carol Mimura,

University of California, Berkeley

Amy P. Patterson,

National Institutes of Health, Maryland

Janet Shoemaker,

American Society for Microbiology, Washington, DC

Lana Skirboll,

National Institutes of Health, Maryland

Nancy S. Sung,

Burroughs Wellcome Fund, North Carolina

Irena Tartakovsky,

Association of American Medical Colleges, Washington, DC

1

IOM forums and roundtables do not issue, review, or approve individual documents. The responsibility for the published workshop summary rests with the workshop rapporteurs and the institution.

Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×

Jorge A. Tavel,

National Institute of Allergy and Infectious Diseases, Maryland

Joanne Waldstreicher,

Johnson & Johnson, New Jersey

Janet Woodcock,

U.S. Food and Drug Administration, Maryland

Raymond L. Woosley,

Critical Path Institute, Arizona

Page viii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×

This page intentionally left blank.

Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×

Reviewers

This report has been reviewed in draft form by individuals chosen for their diverse perspectives and technical expertise, in accordance with procedures approved by the National Research Council’s Report Review Committee. The purpose of this independent review is to provide candid and critical comments that will assist the institution in making its published report as sound as possible and to ensure that the report meets institutional standards for objectivity, evidence, and responsiveness to the study charge. The review comments and draft manuscript remain confidential to protect the integrity of the deliberative process. We wish to thank the following individuals for their review of this report:

Mark Avigan, U.S. Food and Drug Administration, U.S. Department of Health and Human Services

Jacqueline Hunter, GlaxoSmithKline

Neil Kaplowitz, USC Research Center for Liver Diseases, Keck School of Medicine, University of Southern California

Dan M. Roden, Oates Institute for Experimental Therapeutics, Vanderbilt University School of Medicine

Although the reviewers listed above have provided many constructive comments and suggestions, they were not asked to endorse the final draft of the report before its release. The review of this report was overseen by Dr. Johanna T. Dwyer, Tufts University School of Medicine & Friedman School of Nutrition Science & Policy, Frances Stern Nutrition Center, Tufts-

Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×

New England Medical Center. Appointed by the Institute of Medicine, she was responsible for making certain that an independent examination of this report was carried out in accordance with institutional procedures and that all review comments were carefully considered. Responsibility for the final content of this report rests entirely with the authors and the institution.

Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×

Preface

Biomarkers are central to the future of medicine. By providing a measure of a biological state, they can indicate normal biological processes, pathogenic processes, or responses to an intervention or perturbation in the environment. They can be used to monitor the on-target and off-target effects of medical interventions, including treatments for disease; they can be used in diagnostic and prognostic tests; and they can define the individuals and populations most likely to respond to therapy. At the broadest level, they can provide insight into biological pathways and networks.

It is also important to recognize that biomarkers have limitations. In isolation, they reveal just one aspect of complex biological systems. Therefore, they may or may not be correlated with clinical outcomes, since other biological systems may override the particular marker being measured. The work needed to understand the relation of a biomarker to either a clinical outcome or a biological system can be enormous. Yet biomarkers are most powerful when they are linked with knowledge about biological systems, with empirical data about diagnostic and therapeutic trials, or with clinical outcomes derived from large populations. The power of modern biology comes from the ability to integrate disparate bases of knowledge, leading to better decisions.

As the cost of developing drugs has risen and the number of new drugs approved for use has fallen, many people have looked to the development of biomarkers as a way to cut costs, enhance safety, and provide a more focused and rational pathway to drug development. Accordingly, greater regulatory emphasis has been placed on the development and use of biomarkers in drug development, which has increased the urgency of accel-

Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×

erating preclinical and clinical research on these markers and establishing evidentiary standards for their use. Biomarker advocates tend to emphasize the progress that has been made, while many drug development teams and experts in clinical effectiveness are skeptical. In fact, both perspectives have merit, and the workshop summarized in this report provided some reassurance that biomarkers, placed in proper perspective, will advance both biomedical science and the pragmatic science of developing drugs that improve human health. At the same time, the workshop also demonstrated the inability of current biomarkers to substitute fully for actual measurement of the risks and benefits of interventions since multiple biological networks and pathways are always in play.

The workshop’s final sessions considered the increased complexity of validating and qualifying multimarker panels of biomarkers. Until recently, biomarkers had been developed one at a time. But the advent of large-scale genomic, proteomic, metabolomic, and advanced imaging technologies is changing the environment in which biomarkers are identified and assessed. In the final session, speakers explored the potential for applying cutting-edge scientific technologies to enhance the prediction and detection of drug-induced toxicity, discussed the integration of systems biology and computational biology into toxicity assessments early in drug development, and considered the regulatory and scientific challenges involved in the development and use of multimarker panels.

The workshop was not designed to produce consensus on future steps that should be taken, but in the course of the discussion, numerous ideas arose that can provide insight into measures that might be useful. The workshop challenged participants to consider how each individual and group might contribute to advancing this work, and the workshop organizers hope that this publication will do the same for a broader group of readers.


Robert Califf

Workshop Chair

Page xiii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×
Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×
Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×

Tables, Figures, and Boxes

TABLES

3-1

 

Strengths and Weakness of the QTc Interval as a Safety Biomarker,

 

18

4-1

 

Promising Translational Biomarkers of Acute Kidney Injuries,

 

32

4-2

 

Current Deficiencies, Needs, and Proposals to Address Kidney Safety Issues in Early Drug Development,

 

38

5-1

 

Regulatory Actions on Approved Drugs Due to Hepatotoxicity, 1995–2008,

 

44

FIGURES

2-1

 

The number of new molecular entities (NMEs) submitted to the FDA has fallen since the mid-1990s,

 

8

5-1

 

Acute idiosyncratic hepatocellular injury,

 

44

BOXES

2-1

 

The Toll of Mental Illness,

 

15

4-1

 

Initiatives to Advance Understanding of Kidney Safety Biomarkers,

 

33

6-1

 

Systems Biology and Biomarker Development,

 

62

Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×

This page intentionally left blank.

Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×
Page R1
Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×
Page R2
Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×
Page R3
Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×
Page R4
Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×
Page R5
Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×
Page R6
Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×
Page R7
Page viii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×
Page R8
Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×
Page R9
Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×
Page R10
Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×
Page R11
Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×
Page R12
Page xiii Cite
Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×
Page R13
Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×
Page R14
Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×
Page R15
Suggested Citation:"Front Matter." Institute of Medicine. 2009. Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/12587.
×
Page R16
Next: 1 Introduction »
Accelerating the Development of Biomarkers for Drug Safety: Workshop Summary Get This Book
×
Buy Paperback | $29.00 Buy Ebook | $23.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Biomarkers can be defined as indicators of any biologic state, and they are central to the future of medicine. As the cost of developing drugs has risen in recent years, reducing the number of new drugs approved for use, biomarker development may be a way to cut costs, enhance safety, and provide a more focused and rational pathway to drug development.

On October 24, 2008, the IOM's Forum on Drug Discovery, Development, and Translation held "Assessing and Accelerating Development of Biomarkers for Drug Safety," a one-day workshop, summarized in this volume, on the value of biomarkers in helping to determine drug safety during development.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!